Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at Guggenheim

Guggenheim upgraded shares of Bicara Therapeutics (NASDAQ:BCAX) to a strong-buy rating in a report issued on Sunday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. The Goldman Sachs Group boosted their price objective on shares of Bicara Therapeutics from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. HC Wainwright boosted their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Finally, Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.40.

Bicara Therapeutics Trading Up 1.5%

NASDAQ BCAX opened at $22.92 on Friday. Bicara Therapeutics has a 1-year low of $7.80 and a 1-year high of $24.25. The company has a 50 day moving average of $20.74 and a 200-day moving average of $18.08. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -9.06 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.29). On average, equities research analysts forecast that Bicara Therapeutics will post -2.72 earnings per share for the current year.

Insider Activity at Bicara Therapeutics

In other news, insider David Raben sold 16,300 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total transaction of $301,876.00. Following the completion of the transaction, the insider directly owned 55,286 shares in the company, valued at approximately $1,023,896.72. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ivan Hyep sold 13,555 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $18.22, for a total transaction of $246,972.10. Following the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 174,310 shares of company stock valued at $3,459,283 over the last three months.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCAX. Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth $45,000. Larson Financial Group LLC grew its stake in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.